OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TNHM55

Thai Nakarin Hospital PCL

Healthcare Facilities & ServicesVerified

Thai Nakarin Hospital PCL maintains a strong capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative approach to leverage. The company's liquidity is reflected in a current ratio of 5.64, suggesting ample short-term assets to cover liabilities. However, the company holds only THB 200 in cash and equivalents, which is extremely low relative to its total assets of THB 3.86 billion, indicating that liquidity is not a primary focus of its financial strategy. Profitability metrics show a return on equity (ROE) of 11.81% and a return on assets (ROA) of 10.24%, both of which are strong and suggest efficient use of equity and assets to generate returns. These figures are well above the typical thresholds for the healthcare facilities and services industry, where ROE and ROA are often lower due to the capital-intensive nature of the sector. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates. Looking ahead, the company's growth trajectory is supported by a positive operating cash flow of THB 525.5 million and a free cash flow of THB 176.3 million, which provide flexibility for reinvestment or expansion. However, capital expenditures were negative at THB -236.3 million, suggesting asset disposals or a reduction in capital spending, which may signal a strategic shift or a focus on cost optimization. Risk factors for the company are currently low, with no immediate liquidity or dilution flags detected. The company has not issued any recent dilutive instruments, and its shares outstanding remain unchanged at 180 million for both basic and diluted shares. The absence of long-term debt and the strong equity position further reduce financial risk exposure. No recent filings or transcripts were identified that would indicate significant changes in the company's operations or strategy. The company appears to be maintaining a stable financial position without major external disruptions.

30-day price · TNHM(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyThai Nakarin Hospital PCL
TickerTNHM.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Thai Nakarin Hospital PCL operates as a healthcare provider in the healthcare facilities and services industry, generating revenue primarily through medical services and patient care.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Thai Nakarin Hospital PCL maintains a strong capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative approach to leverage. The company's liquidity is reflected in a current ratio of 5.64, suggesting ample short-term assets to cover liabilities. However, the company holds only THB 200 in cash and equivalents, which is extremely low relative to its total assets of THB 3.86 billion, indicating that liquidity is not a primary focus of its financial strategy. Profitability metrics show a return on equity (ROE) of 11.81% and a return on assets (ROA) of 10.24%, both of which are strong and suggest efficient use of equity and assets to generate returns. These figures are well above the typical thresholds for the healthcare facilities and services industry, where ROE and ROA are often lower due to the capital-intensive nature of the sector. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates. Looking ahead, the company's growth trajectory is supported by a positive operating cash flow of THB 525.5 million and a free cash flow of THB 176.3 million, which provide flexibility for reinvestment or expansion. However, capital expenditures were negative at THB -236.3 million, suggesting asset disposals or a reduction in capital spending, which may signal a strategic shift or a focus on cost optimization. Risk factors for the company are currently low, with no immediate liquidity or dilution flags detected. The company has not issued any recent dilutive instruments, and its shares outstanding remain unchanged at 180 million for both basic and diluted shares. The absence of long-term debt and the strong equity position further reduce financial risk exposure. No recent filings or transcripts were identified that would indicate significant changes in the company's operations or strategy. The company appears to be maintaining a stable financial position without major external disruptions.
Key takeaways
  • Thai Nakarin Hospital PCL has a strong return on equity (11.81%) and return on assets (10.24%), indicating efficient capital use.
  • The company is debt-free with a current ratio of 5.64, suggesting strong short-term liquidity.
  • Revenue is concentrated in a single business segment, which may increase operational risk.
  • Capital expenditures were negative, indicating a reduction in investment or asset disposals.
  • No immediate liquidity or dilution risks are present, and the company has not issued new shares recently.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$2.77B
Gross profit$719.1M
Operating income$465.7M
Net income$394.8M
R&D
SG&A
D&A
SBC
Operating cash flow$525.5M
CapEx-$236.3M
Free cash flow$176.3M
Total assets$3.86B
Total liabilities$513.0M
Total equity$3.34B
Cash & equivalents$200.00
Long-term debt$0.00
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$3.34B
Net cash$200.00
Current ratio5.6
Debt/Equity0.0
ROA10.2%
ROE11.8%
Cash conversion1.3%
CapEx/Revenue-8.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricTNHMActivity
Op margin16.8%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin14.2%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin26.0%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-8.5%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity0.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 01:17 UTC#dad46614
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 18:10 UTCJob: 6c6a4c6a